Salix Pharmaceuticals Announces 4Q2006 and FY2006 Financial Results Conference Call and Webcast.RALEIGH, N.C. -- Salix Pharmaceuticals, Ltd. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :SLXP) today announced that the Company will report fourth quarter and full year ended December 31, 2006 financial results before the market opens on Wednesday, February 28, 2007. The Company will host a conference call at 9:00 a.m. ET, on Wednesday, February 28, 2007. Interested parties can access the conference call by way of web cast or telephone. The live web cast will be available at http://www.salix.com. A replay of the web cast will be available at the same location. The telephone numbers to access the conference call are (800) 479-9001 (U.S. and Canada) or (719) 457-2618 (international.) The access code for the call is 5114993. A replay of the call will be available from 12:00 noon ET. The telephone numbers to access the replay of the call are (888) 203-1112 (U.S. and Canada) or (719) 457-0820 (international.) The access code for the replay is 5114993. Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina For other uses of this name, see Raleigh. Raleigh (IPA: /ˈrɑli/, ral-ee) is the capital of the State of North Carolina and the county seat of Wake County. , develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. Salix's strategy is to in-license late-stage or marketed proprietary therapeutic drugs, complete any required development and regulatory submission of these products, and market them through the Company's gastroenterology gastroenterology Medical specialty dealing with digestion and the digestive system. In the 17th century Jan Baptista van Helmont conducted the first scientific studies in the field; William Beaumont published his own observations in 1833. specialty sales and marketing team. Salix also markets XIFAXAN([R]), VISICOL([R]), OSMOPREP[TM], AZASAN([R]), ANUSOL-HC([R]) and PROCTOCORT([R]). In August 2006, the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approved MOVIPREP([R])for bowel cleansing prior to colonoscopy Colonoscopy Definition Colonoscopy is a medical procedure where a long, flexible, tubular instrument called the colonoscope is used to view the entire inner lining of the colon (large intestine) and the rectum. , and we intend to launch the product in mid-fourth quarter 2006. Balsalazide tablets, Granulated gran·u·late v. gran·u·lat·ed, gran·u·lat·ing, gran·u·lates v.tr. 1. To form into grains or granules. 2. To make rough and grainy. v.intr. Mesalamine, SANVAR([R]) (600 ug vials vapreotide acetate powder) and Xifaxan for additional indications are under development. Salix trades on the NASDAQ Market under the ticker symbol Ticker Symbol An arrangement of characters (usually letters) representing a particular security listed on an exchange or otherwise traded publicly. When a company issues securities to the public marketplace, it selects an available ticker symbol for its securities which investors "SLXP." For more information please contact the Company at 919-862-1000 or visit our web site at www.salix.com. Information on our web site is not incorporated in our SEC filings. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion